Merck acquires Acceleron in $11.5B deal

Thursday, 30. September 2021 12:55

Merck and Co. has finalized the arrangement worth approximately $11.5 billion in which it will acquire the pharmaceutical company Acceleron Pharma Inc., the two companies confirmed on Thursday.

Via a subsidiary, Merck will buy Acceleron for $180 per share, the statement read.

"Acceleron's innovative research has yielded an exciting late-stage candidate that complements and strengthens our growing cardiovascular portfolio and pipeline and holds the potential to build upon Merck's proud legacy in cardiovascular disease," Merck CEO Rob Davis commented.

Acceleron's shares rose nearly 2% in the premarket after the announcement.

Related Links: Merck KGaA
Baha Breaking the News (BBN) / BU